UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000003040
Receipt number R000003325
Scientific Title Randomized comparison of Sequential therapies with Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma
Date of disclosure of the study information 2010/01/15
Last modified on 2014/07/15 16:53:26

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Randomized comparison of Sequential therapies with Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma

Acronym

CROSS-J-RCC

Scientific Title

Randomized comparison of Sequential therapies with Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma

Scientific Title:Acronym

CROSS-J-RCC

Region

Japan


Condition

Condition

renal cell cancer

Classification by specialty

Urology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

The clinical benefits of sunitinib and sorafenib have been demonstrated in patients with cytokine-refractory metastatic renal cell carcinoma. Sunitinib has also been shown to improve progression free survival and overall survival in a comparative study with interferon-alpha. When sunitinib is used as first-line molecular-targeted therapy, switching to sorafenib is one of the treatment options after disease progression. Reversely, when sorafenib is used as first-line molecular-targeted therapy, sunitinib is used as second-line therapy. The goal of cancer treatment is cure, and if cure is not possible, it is to prolong survival. In this study, sunitinib or sorafenib will be administered as first-line molecular-targeted therapy and treatment switched to the other test drug, sorafenib or sunitinib, when disease progression is detected to assess which treatment sequence produces longer progression free survival and offers a better safety profile (causing fewer adverse events). The purpose of this trial is to compare progression free survival of first line sunitinib versus sorafenib, and that of two treatment sequences, i.e. sunitinib followed by sorafenib versus sorafenib followed by sunitinib.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Not applicable


Assessment

Primary outcomes

PFS in first-line treatment, Total progression free survival (PFS) in first-line and second-line treatments

Key secondary outcomes

PFS in second-line treatment, Antitumor effect, survival, clinical benefit (CR+PR+NC), and adverse event


Base

Study type

Interventional


Study design

Basic design

Cross-over

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

YES

Dynamic allocation

YES

Institution consideration

Institution is considered as adjustment factor in dynamic allocation.

Blocking

NO

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

sunitinib administration, washout period, sorafenib administration

Interventions/Control_2

sorafenib administration, washout period, sunitinib administration

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

20 years-old <=

Age-upper limit

80 years-old >=

Gender

Male and Female

Key inclusion criteria

1) Age: 20-80 years old, both inclusive
2) ECOG performance status of 0, 1, or 2
3) MSKCC risk of favorable or intermediate
4) Histologically confirmed renal cell carcinoma
5) No ischemic heart disease
6) Laboratory findings meet the following criteria:
(1) Respiratory function: %VC, 80% and FEV1.0,70%
(2) Hematology: white blood cell count4,000/mm3, platelet count100,000/mm3
(3) Clinical chemistry: GOT and GPT within the normal range of each medical institution; total bilirubin <1.5 x ULN
(4) Serum creatinin <2.0mg/dl, blood urea nitrogen (BUN) <25mg/dl
(5) Echocardiographic estimation of left ventricular ejection fraction is higher than the lower limit of reference range of each medical institution.

Key exclusion criteria

1) History of any other malignancy
2) Central nervous system metastases. However, patients who remain asymptomatic, have no new or enlarging lesion in the CNS within 6 months of enrollment in this study, and require no corticosteroids may be enrolled.
3) History of cardiac infarction, unstable angina, congestive heart failure, or symptomatic peripheral vascular disease within 12 months of enrollment
4) History of cerebrovascular disorder including transient ischemic attack (TIA)
5) Pregnancy or possible pregnancy at any time during the study
6) Ongoing grade 2 adverse event prior treatment
7) Prior treatment with any anticancer therapy including cytokine therapy such as interferon-alpha and interleukin-2
8) Prior treatment with mTOR inhibitor
9) Prior treatment with sunitinib or sorafenib
10) Treatment with an test drug in a clinical research within 4 weeks of enrollment in this study

Target sample size

120


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Yoshihiko Tomita

Organization

Yamagata University

Division name

Faculty of Medicine, Department of Urology

Zip code


Address

Iida-nishi 2-2-2, Yamagata

TEL

023-628-5368

Email

ytomita@med.id.yamagata-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Yoshihiko Tomita

Organization

Yamagata University

Division name

Faculty of Medicine, Department of Urology

Zip code


Address

Iida-nishi 2-2-2, Yamagata

TEL

023-628-5368

Homepage URL


Email

ytomita@med.id.yamagata-u.ac.jp


Sponsor or person

Institute

Yamagata University Faculty of Medicine

Institute

Department

Personal name



Funding Source

Organization

Yamagata University Faculty of Medicine

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

YES

Study ID_1

CT01481870

Org. issuing International ID_1

Clinical Trials

Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

旭川医科大学附属病院(北海道)
札幌医科大学附属病院(北海道)
北海道大学病院(北海道)
函館五稜郭病院(北海道)
弘前大学医学部附属病院(青森県)
秋田大学医学部附属病院(秋田県)
岩手医科大学附属病院(岩手県)
東北大学医学部附属病院(宮城県)
山形大学医学部付属病院(山形県)
獨協医科大学病院(栃木県)
埼玉医科大学総合医療センター(埼玉県)
防衛医科大学校病院(埼玉県)
東京女子医科大学病院(東京都)
日本大学医学部附属板橋病院(東京都)
慶応義塾大学病院(東京都)
北里大学病院(東京都)
東京慈恵会医科大学附属病院(東京都)
東京大学医学部附属病院(東京都)
日本医科大学付属病院(東京都)
千葉県がんセンター(千葉県)
神奈川県立がんセンター(神奈川県)
山梨大学医学部附属病院(山梨県)
新潟大学医歯学総合病院(新潟県)
新潟市民病院(新潟県)
県立がんセンター新潟病院(新潟県)
金沢大学付属病院(石川県)
岐阜大学医学部附属病院(岐阜県)
名古屋大学医学部附属病院(愛知県)
藤田衛生保険大学(愛知県)
京都大学附属病院(京都府)
天理よろず病院相談所病院(奈良県)
岡山大学病院(岡山県)
広島市民病院(広島県)
島根大学医学部付属病院(島根)
徳島大学病院(徳島県)
香川大学医学部附属病院(香川県)
四国がんセンター(愛媛県)
山口大学医学部附属病院(山口県)
大分大学医学部附属病院(大分県)
広島大学病院(広島県)
広島市民病院(広島県)
山口大学附属病院(山口県)
長崎大学附属病院(長崎県)
鹿児島大学病院(鹿児島県)
宮崎大学医学部附属病院(宮崎県)
琉球大学医学部附属病院(沖縄県)


Other administrative information

Date of disclosure of the study information

2010 Year 01 Month 15 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2010 Year 01 Month 13 Day

Date of IRB


Anticipated trial start date

2010 Year 01 Month 01 Day

Last follow-up date

2015 Year 12 Month 01 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2010 Year 01 Month 15 Day

Last modified on

2014 Year 07 Month 15 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000003325


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name